<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848820</url>
  </required_header>
  <id_info>
    <org_study_id>APAC2016</org_study_id>
    <nct_id>NCT02848820</nct_id>
  </id_info>
  <brief_title>Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children</brief_title>
  <acronym>APAC</acronym>
  <official_title>Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children Aged 7-17 Years Old - Antibiotics Versus Primary Appendectomy in Children With Simple Appendicitis: APAC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramon Gorter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE

      The aim of this study is to compare the effectiveness of initial non-operative treatment
      strategy (reserving appendectomy for those not responding or with recurrent disease) with
      immediate appendectomy in children from 7 to 17 years old, inclusive, with acute simple
      appendicitis in terms of complications, health-related QOL and costs.

      Main research question: What is the difference in proportion of patients experiencing
      complications within 1 year between both strategies in children from 7 to 17 years old,
      inclusive, with acute simple appendicitis?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial non-operative treatment of acute simple appendicitis has recently been investigated
      in both the adult as the paediatric population. In the adult population, six Randomised
      Controlled Trial (RCTs) showed that an appendectomy could be avoided in 40-76% of the
      patients at the end of their follow-up period. Despite the fact that some patients need to
      undergo a delayed appendectomy, it has been demonstrated in systematic reviews that
      non-operative treatment strategy is associated with a significant reduction in complications,
      faster recovery and return to work, less pain duration and analgesic medication consumption.
      In children only pilot data is yet available. Short-term success rates of this strategy
      (including of the investigators own pilot cohort study) are between the 83-92%. Long-term
      results (one-year follow-up) are available from two studies; 62-75% did not require an
      appendectomy. No large RCT have yet been conducted in the paediatric population. It is
      therefore essential to generate high quality empirical evidence regarding this strategy in
      this subset of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing complications</measure>
    <time_frame>One year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days absent from school, social or sport events</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days absent from work</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of extra visits (not the already scheduled ones) to the outpatient clinic, general practitioners office or emergency department for abdominal pain.</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of hospital stay during the follow-up period for strategy related treatment or complications</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of analgesics medication use.</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score measured by the Visual Analogue Scale (VAS)</measure>
    <time_frame>Clinical phase (up to 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with missed diagnosis of complex appendicitis with risk of peritonitis</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients not having to undergone appendectomy</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing recurrent appendicitis</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing early failure of initial non-operative treatment.</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that undergo interval appendectomy.</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (CHQ-CF87, EQ-5d-Youth, EQ-5d-Proxy)</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical and non-medical costs (Health and Labor questionnaire)</measure>
    <time_frame>1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality adjusted life years (QALY's). Calculating using outcome 13 and 14</measure>
    <time_frame>1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction questionnaire (PSQ-18 &amp; Net promotor score)</measure>
    <time_frame>7 days, 1,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promoting and obstructing factors of implementability measured by questionnaires</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Appendicitis</condition>
  <arm_group>
    <arm_group_label>Augmentin + Gentamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:
Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.
Pain medication according to national protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Operative treatment strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin + Gentamicin</intervention_name>
    <description>Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours</description>
    <arm_group_label>Augmentin + Gentamicin</arm_group_label>
    <other_name>Amoxicillin/clavulanic acid (Augmentin) + Gentamicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Appendectomy</intervention_name>
    <description>Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics</description>
    <arm_group_label>Operative treatment strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 7-17 years

          -  Radiologically confirmed simple appendicitis, defined as:

               1. Clinical findings:

                    -  Unwell, but not generally ill

                    -  Localized tenderness in the right iliac fossa region

                    -  Normal/hyperactive bowel sounds

                    -  No guarding

                    -  No mass palpable

               2. Ultrasonography:

                    -  Incompressible appendix with an outer diameter of ≥6 mm

                    -  Hyperaemia within the appendiceal wall

                    -  Without faecolith

                    -  Infiltration of surrounding fat

                    -  No signs of perforation

                    -  No signs of intra-abdominal abscess/phlegmon

        Exclusion Criteria:

          -  Generalized peritonitis, complex appendicitis or sepsis (based upon predefined
             criteria and scoring system).

          -  Scoring system: As scoring system was developed determining the risk of complex
             appendicitis based upon five pre-operative variable. Points have been awarded to each
             variable. In case the total score is less than 4 points, the patient is likely to have
             a simple appendicitis. In case the score is 4 or more points, the chance of having
             complex appendicitis is significant and those children will be excluded from this
             study. Variables:

               -  Diffuse abdominal guarding (3 points)

               -  C-Reactive Protein level more than 38 mg/L (2 points)

               -  Signs on ultrasound indicative of complex appendicitis (2 points)

               -  More than one day abdominal pain (2 points)

               -  Temperature: more than 37.5 degree Celsius (1 point)

          -  Faecolith (ultrasound)

          -  Serious co-morbidity

          -  Recurrent appendicitis

          -  Suspicion of an underlying malignancy or inflammatory bowel disease

          -  Documented type 1 allergy to the antibiotics used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst van Heurn, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Surgical Center of Amsterdam (VUmc &amp; AMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Gorter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Surgical Center of Amsterdam (VUmc &amp; AMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roel Bakx, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Surgical Center of Amsterdam (VUmc &amp; AMC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramon Gorter, MD</last_name>
    <phone>0031-205665693</phone>
    <email>rr.gorter@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taco Bijlsma, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Taco Bijlsma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaas in 't Hof, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Klaas in 't Hof, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Bakx, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Roel Bakx, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Bakx, MD PhD</last_name>
      <phone>0031-204442424</phone>
      <email>r.bakx@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Roel Bakx, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Hospital</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugo Bolhuis</last_name>
    </contact>
    <investigator>
      <last_name>Hugo Bolhuis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Red Cross Hospital</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huib Cense, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Huib Cense, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima medical center</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Benders, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>M Benders, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Hospital</name>
      <address>
        <city>Goes</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Jansen, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>J Jansen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elkerliek hospital</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Guijt, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Guijt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wim van Gemert, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Wim van Gemert, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Go, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Go, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivo de Blaauw, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ivo de Blaauw, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rene Wijnen, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rene Wijnen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Hulsker, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Hulsker, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Ramon Gorter</investigator_full_name>
    <investigator_title>drs.</investigator_title>
  </responsible_party>
  <keyword>Appendicitis</keyword>
  <keyword>Appendectomy</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Appendicitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will follow</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

